2018
Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies
Martin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.Peer-Reviewed Original ResearchConceptsPI-RADSv2 scoreDecipher scoreProstate Imaging ReportingDecipher testingTargeted biopsiesRadical prostatectomyData System version 2 (PI-RADS v2) scoreFavorable intermediate-risk prostate cancerIntermediate-risk prostate cancer patientsGleason Grade Group 1Imaging ReportingIntermediate-risk prostate cancerMultivariable logistic regression analysisHigh-risk diseasePI-RADS 4Grade group 1Gleason grade groupProstate cancer patientsMultiparametric magnetic resonancePI-RADS scoreVersion 2 scoreData System scoreLogistic regression analysisSignificant differencesPI-RADS category
2017
Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volume
2016
Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms
Kristiansen G, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P, Epstein J, Graduierungskommittee. Konsenskonferenz 2014 der ISUP zur Gleason-Graduierung des Prostatakarzinoms. Die Pathologie 2016, 37: 17-26. PMID: 26809207, DOI: 10.1007/s00292-015-0136-6.Peer-Reviewed Original Research
2015
NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence
Manda K, Tripathi P, Hsi A, Ning J, Ruzinova M, Liapis H, Bailey M, Zhang H, Maher C, Humphrey P, Andriole G, Ding L, You Z, Chen F. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene 2015, 35: 3282-3292. PMID: 26477312, PMCID: PMC5012433, DOI: 10.1038/onc.2015.389.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCell LineCell Line, TumorCell ProliferationCell Transformation, NeoplasticCellular SenescenceCytokinesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMice, KnockoutMice, NudeMice, TransgenicNFATC Transcription FactorsProstateProstatic NeoplasmsPTEN PhosphohydrolaseReverse Transcriptase Polymerase Chain ReactionTransplantation, HomologousTumor Cells, CulturedTumor MicroenvironmentConceptsProstate tumorigenesisHuman PCaNFATc1 activationNon-tumorigenic prostate cellsActivated T cells c1Cultured PCa cellsT cells c1Cellular senescenceRole of NFATc1Number of cytokinesActivation of NFATc1Proinflammatory cytokinesPCa cellsProstate cancerProstatic adenocarcinomaLuminal epitheliumMouse prostateCells c1Normal prostateOncogenic roleOncogene c-mycProstate tissueProstate cellsSoluble factorsNuclear factor
2009
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis
Song H, Zhang B, Watson M, Humphrey P, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009, 28: 3307-3319. PMID: 19597465, PMCID: PMC2746257, DOI: 10.1038/onc.2009.181.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtrophyClusterinDisease Models, AnimalDisease ProgressionDown-RegulationGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansLasersMaleMiceMicrodissectionOxidoreductases Acting on Sulfur Group DonorsProstateProstatic NeoplasmsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseSignal TransductionThioredoxinsTranscription FactorsTranscription, GeneticTranscriptional ActivationConceptsNKX3.1 lossMolecular consequencesGene expressionProstate tumorigenesisPTEN-AKTCancer initiationProstate cancer initiationCohort of genesNumber of genesC-Myc signaling pathwayDownstream target genesHuman prostate tumorigenesisLoss of NKX3.1NKX3.1 expressionTumor suppressor geneGene expression data setsExpression data setsQuiescin Q6Transcriptional regulatorsIndependent lossesExpression of NKX3.1Laser capture microdissectionTarget genesCancer gene expression data setsSignaling pathways
2008
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
Brimo F, Vollmer R, Corcos J, Kotar K, Bégin L, Humphrey P, Bismar T. Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 2008, 53: 177-183. PMID: 18752501, DOI: 10.1111/j.1365-2559.2008.03087.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiopsy, NeedleHumansMaleMiddle AgedPredictive Value of TestsPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsConceptsPathological stageTumor lengthPrognostic valueTumor extentFinal pathological stageHigher stage diseaseNeedle biopsy specimenCancer patient outcomesPrognostic significanceBiochemical recurrenceBiopsy specimenRadical prostatectomyPatient outcomesBiopsy reportingFailure statusCancer lengthPositive coresPathological outcomesLarger studyMorphometric measurementsDiscontinuous fociCancerCore tissuePatientsOutcomes
2004
EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
ANDRIOLE G, HUMPHREY P, RAY P, GLEAVE M, TRACHTENBERG J, THOMAS L, LAZIER C, RITTMASTER R. EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER. Journal Of Urology 2004, 172: 915-919. PMID: 15310997, DOI: 10.1097/01.ju.0000136430.37245.b9.Peer-Reviewed Original ResearchConceptsProstate cancerMicrovessel densityDutasteride treatmentIntraprostatic dihydrotestosteroneTumor regressionDual 5α-Reductase Inhibitor DutasterideShort-term pilot studyDays of placeboEffect of dutasterideIntraprostatic androgen levelsT2 prostate cancerDegree of atrophyProstate cancer treatmentShort-term treatmentProstate cancer tissuesIndex of apoptosisRadical prostatectomyEarly treatmentAndrogen levelsDutasterideCancer tissuesResected tissuesDHT formationDihydrotestosteroneType 1
2001
The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer
Vollmer R, Humphrey P. The Relative Importance of Anatomic and PSA Factors to Outcomes After Radical Prostatectomy for Prostate Cancer. American Journal Of Clinical Pathology 2001, 116: 864-870. PMID: 11764075, DOI: 10.1309/7mq7-mwar-4w8a-r75f.Peer-Reviewed Original ResearchConceptsElevated PSA levelsEarly deathPSA levelsRadical prostatectomyProstate cancerPathology observationsGleason grade 5Overall good prognosisTime of prostatectomyPostoperative levelsPSA failureStudy patientsBetter prognosisProgressive tumorsPrognostic categoriesPercentage carcinomaProstatectomySubsequent outcomesLower hazardDeathSurgeryHigher hazardCancerMenPSAFrequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma
Abdulkadir S, Carbone J, Naughton C, Humphrey P, Catalona W, Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Human Pathology 2001, 32: 935-939. PMID: 11567222, DOI: 10.1053/hupa.2001.27102.Peer-Reviewed Original ResearchConceptsHuman prostate cancerHuman prostate carcinomaProstate cancerProstate carcinomaProstatic intraepithelial neoplasia lesionsIntraepithelial neoplasia lesionsProstate carcinoma specimensExpression of Nab2Prostate tumor suppressorNeoplasia lesionsTumor gradeCarcinoma specimensProstate tumorigenesisTumor progressionTranscription factor EGR1Protein expressionEarly lossEGR1 levelsCarcinomaTumorigenic processCancerTumor suppressorSame stimuliEGR1Transcriptional activityLatent Prostate Carcinoma in a Screened Population
Kibel A, Humphrey P. Latent Prostate Carcinoma in a Screened Population. European Urology 2001, 39: 35-36. PMID: 11340287, DOI: 10.1159/000052583.Peer-Reviewed Original ResearchSCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER
NAUGHTON M, PICUS J, ZHU X, CATALONA W, VOLLMER R, HUMPHREY P. SCATTER FACTOR-HEPATOCYTE GROWTH FACTOR ELEVATION IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. Journal Of Urology 2001, 165: 1325-1328. PMID: 11257710, DOI: 10.1016/s0022-5347(01)69893-8.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseHepatocyte growth factorPatient ageSerum levelsNegative sextant prostate biopsiesProstate-specific antigen levelHuman prostate cancer cell linesAvailable enzyme-linked immunosorbentSextant prostate biopsySpecific antigen levelsNegative sextant biopsiesProstate cancer cell linesSera of patientsImportant serum markerLogistic regression analysisEnzyme-linked immunosorbentCancer cell linesLocalized cancerRadiographic evidenceSerum markersAntigen levelsSextant biopsyProstate biopsyImpaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir S, Qu Z, Garabedian E, Song S, Peters T, Svaren J, Carbone J, Naughton C, Catalona W, Ackerman J, Gordon J, Humphrey P, Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nature Medicine 2001, 7: 101-107. PMID: 11135623, DOI: 10.1038/83231.Peer-Reviewed Original ResearchConceptsEarly growth response protein 1Prostate cancerTumor progressionProstatic intra-epithelial neoplasiaEgr1 deficiencyIntra-epithelial neoplasiaHigh-resolution magnetic resonance imagingTransgenic mouse modelHuman prostate cancerTumor growth rateEgr1-deficient miceMagnetic resonance imagingProstate tumor progressionMouse modelProstate tumorigenesisSurvival analysisResonance imagingCarcinomaTumor developmentProtein 1ProgressionCancerMiceDeficiencyEGR1Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists
Allsbrook W, Mangold K, Johnson M, Lane R, Lane C, Amin M, Bostwick D, Humphrey P, Jones E, Reuter V, Sakr W, Sesterhenn I, Troncoso P, Wheeler T, Epstein J. Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists. Human Pathology 2001, 32: 74-80. PMID: 11172298, DOI: 10.1053/hupa.2001.21134.Peer-Reviewed Original ResearchMeSH KeywordsHumansMaleNeoplasm StagingObserver VariationPathology, ClinicalProstateProstatic NeoplasmsReproducibility of ResultsUrologyConceptsUrologic pathologistsProstatic carcinomaInterobserver reproducibilityGleason scoreGleason gradingGleason grade groupLow-grade tumorsCribriform proliferationNeedle biopsyGroup 2Gleason patternGrading systemCarcinomaGrade groupTumorsPathologistsScoresGradingKappa coefficientBiopsyHistologyCoefficient kappa
2000
Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma
Zhu X, Humphrey P. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000, 56: 1071-1074. PMID: 11113771, DOI: 10.1016/s0090-4295(00)00795-0.Peer-Reviewed Original ResearchConceptsPlatelet-derived growth factorVascular endothelial growth factorHGF expressionSF/HGF expressionEndothelial growth factorGrowth factorProstatic carcinomaIL-1betaStromal myofibroblastsProstatic tissueSF/HGFCarcinoma tissuesGrowth factors basic fibroblast growth factorCell linesProstatic epithelial cell linesHuman prostatic carcinoma tissueHuman prostatic tissue samplesProstatic tissue samplesProstatic carcinoma tissueBenign prostatic tissueHuman prostatic carcinomaHuman prostatic tissueMalignant human prostatic tissuesMultifunctional polypeptide growth factorsEnzyme-linked immunosorbentMinimal Adenocarcinoma in Prostate Needle Biopsy Tissue
Thorson P, Humphrey P. Minimal Adenocarcinoma in Prostate Needle Biopsy Tissue. American Journal Of Clinical Pathology 2000, 114: 896-909. PMID: 11338479, DOI: 10.1309/kvpx-c1em-142l-1m6w.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAtrophyBiopsy, NeedleDiagnosis, DifferentialHumansHyperplasiaImmunohistochemistryKeratinsMaleProstatic NeoplasmsConceptsNeedle biopsy tissueProstate needle biopsy tissueMinor diagnostic criteriaBiopsy tissueProstatic adenocarcinomaDiagnostic criteriaMinimal adenocarcinomaHigh-grade prostatic intraepithelial neoplasiaAtypical small acinar proliferationFocal glandular atypiaValuable adjunctive studySmall acinar proliferationProstatic intraepithelial neoplasiaAtypical adenomatous hyperplasiaConstellation of findingsIntermediate histologic gradeMajor diagnostic challengeWhole prostate glandVisual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy
Carvalhal G, Humphrey P, Thorson P, Yan Y, Ramos C, Catalona W. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000, 89: 1308-1314. PMID: 11002227, DOI: 10.1002/1097-0142(20000915)89:6<1308::aid-cncr16>3.0.co;2-3.Peer-Reviewed Original ResearchConceptsPercentage of carcinomaGroup of patientsDisease recurrenceRadical prostatectomyRadical prostatectomy specimensIndependent predictorsPathologic stageGleason scoreTumor recurrenceProstate carcinomaProstatectomy specimensPreoperative prostate-specific antigen levelProstate-specific antigen levelKaplan-Meier product limit estimatesCox proportional hazards modelProstatic tissue specimensPathologic tumor stageKaplan-Meier methodRecurrence-free survivalSpecific antigen levelsImportant prognostic informationCox proportional hazardsProportional hazards modelProstate carcinoma recurrenceTumor size measurementsTissue factor expression and angiogenesisin human prostate carcinoma
Abdulkadir S, Carvalhal G, Kaleem Z, Kisiel W, Humphrey P, Catalona W, Milbrandt J. Tissue factor expression and angiogenesisin human prostate carcinoma. Human Pathology 2000, 31: 443-447. PMID: 10821491, DOI: 10.1053/hp.2000.6547.Peer-Reviewed Original Research
1999
Genetic Analysis of Prostatic Atypical Adenomatous Hyperplasia (Adenosis)
Doll J, Zhu X, Furman J, Kaleem Z, Torres C, Humphrey P, Donis-Keller H. Genetic Analysis of Prostatic Atypical Adenomatous Hyperplasia (Adenosis). American Journal Of Pathology 1999, 155: 967-971. PMID: 10487854, PMCID: PMC1866890, DOI: 10.1016/s0002-9440(10)65196-6.Peer-Reviewed Original ResearchMeSH KeywordsAllelesChromosomes, HumanHumansLoss of HeterozygosityMaleMicrosatellite RepeatsPrecancerous ConditionsProstatic HyperplasiaProstatic Neoplasms
1998
A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
Garabedian E, Humphrey P, Gordon J. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 15382-15387. PMID: 9860977, PMCID: PMC28051, DOI: 10.1073/pnas.95.26.15382.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstatic intraepithelial neoplasiaTransgenic mouse modelProstate cancerIntraepithelial neoplasiaMouse modelNeuroendocrine cellsHuman prostate cancerNeuroendocrine cell lineagesWeeks of ageNeuroendocrine differentiationSimian virus 40 T antigenLocal invasionMouse prostateCancerNeoplasiaProstateWeeksT antigenCell lineagesTransgene expressionMultiple pedigreesCellsMetastasisAndrogensClinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study
Naughton C, Smith D, Humphrey P, Catalona W, Keetch D. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998, 52: 808-813. PMID: 9801104, DOI: 10.1016/s0090-4295(98)00344-6.Peer-Reviewed Original ResearchConceptsProstate cancerBiopsy coresCore biopsySextant core biopsiesProstate volumeTotal prostate-specific antigen valuesProstate-specific antigen valuesMore biopsy coresMore biopsy sessionsPathologic tumor characteristicsPathologic tumor featuresSix-core biopsyTotal biopsy coresTRUS prostate volumeNegative prostate biopsyClinical prostate cancerMore biopsy samplesProstate cancer detectionPSA densityProspective trialInitial biopsyPathologic characteristicsProstatic volumeSerum tPSATumor characteristics